PMID- 26687627
OWN - NLM
STAT- MEDLINE
DCOM- 20160928
LR  - 20220819
IS  - 1096-0023 (Electronic)
IS  - 1043-4666 (Linking)
VI  - 78
DP  - 2016 Feb
TI  - Blockade of TGF-beta-activated kinase 1 prevents advanced glycation end 
      products-induced inflammatory response in macrophages.
PG  - 62-8
LID - S1043-4666(15)30112-5 [pii]
LID - 10.1016/j.cyto.2015.11.023 [doi]
AB  - Advanced glycation end products (AGEs), inflammatory-activated macrophages are 
      essential in the initiation and progression of diabetic nephropathy (DN). 
      TGF-beta-activated kinase 1 (TAK1) plays a vital role in innate immune responses and 
      inflammation. However, little information has been available about the effects of 
      AGEs on the regulation of TAK1 expression and underlying mechanisms in 
      AGEs-stimulated macrophage activation. We hypothesized TAK1 signal pathway in 
      AGEs conditions could be a vital factor contributing to macrophage activation and 
      inflammation. Thus, in the present study, we used bone marrow-derived macrophages 
      (BMMs) to explore the functional role and potential mechanisms of TAK1 pathway 
      under AGEs conditions. Results indicated that TAK1 played important roles in 
      AGEs-induced mitogen-activated protein kinases (MAPKs) and nuclear factor kappa B 
      protein (NF-kappaB) activation, which regulated the production of monocyte 
      chemo-attractant protein-1 (MCP-1) and tumor necrosis factor-alpha (TNF-alpha) in 
      AGEs-stimulated macrophages. The results also suggested that TAK1 inhibitor 
      (5Z-7-oxozeaenol) could inhibit AGEs-induced macrophage activation to 
      down-regulate inflammatory cytokine production via MAPKs and NF-kappaB pathways, 
      indicating that 5Z-7-oxozeaenol might be an immunoregulatory agent against 
      AGEs-stimulated inflammatory response in DN.
CI  - Copyright (c) 2015 Elsevier Ltd. All rights reserved.
FAU - Xu, Xingxin
AU  - Xu X
AD  - Department of Nephrology, the First Affiliated Hospital, Anhui Medical 
      University, Hefei, Anhui, PR China.
FAU - Qi, Xiangming
AU  - Qi X
AD  - Department of Nephrology, the First Affiliated Hospital, Anhui Medical 
      University, Hefei, Anhui, PR China.
FAU - Shao, Yunxia
AU  - Shao Y
AD  - Department of Nephrology, the First Affiliated Hospital, Anhui Medical 
      University, Hefei, Anhui, PR China.
FAU - Li, Yuanyuan
AU  - Li Y
AD  - Department of Nephrology, the First Affiliated Hospital, Anhui Medical 
      University, Hefei, Anhui, PR China.
FAU - Fu, Xin
AU  - Fu X
AD  - Department of Nephrology, the First Affiliated Hospital, Anhui Medical 
      University, Hefei, Anhui, PR China.
FAU - Feng, Shiyao
AU  - Feng S
AD  - Department of Nephrology, the First Affiliated Hospital, Anhui Medical 
      University, Hefei, Anhui, PR China.
FAU - Wu, Yonggui
AU  - Wu Y
AD  - Department of Nephrology, the First Affiliated Hospital, Anhui Medical 
      University, Hefei, Anhui, PR China. Electronic address: wuyonggui@medmail.com.cn.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20151210
PL  - England
TA  - Cytokine
JT  - Cytokine
JID - 9005353
RN  - 0 (7-oxozeanol)
RN  - 0 (Ccl2 protein, mouse)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Glycation End Products, Advanced)
RN  - 0 (NF-kappa B)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 5W827M159J (Zearalenone)
RN  - EC 2.7.11.25 (MAP Kinase Kinase Kinases)
RN  - EC 2.7.11.25 (MAP kinase kinase kinase 7)
SB  - IM
MH  - Animals
MH  - Cells, Cultured
MH  - Chemokine CCL2/metabolism
MH  - Diabetic Nephropathies/physiopathology
MH  - Down-Regulation
MH  - Glycation End Products, Advanced/*metabolism
MH  - Inflammation
MH  - MAP Kinase Kinase Kinases/antagonists & inhibitors/*deficiency
MH  - *Macrophage Activation
MH  - Macrophages/*immunology
MH  - Mice
MH  - NF-kappa B/metabolism
MH  - Signal Transduction
MH  - Tumor Necrosis Factor-alpha/metabolism
MH  - Zearalenone/analogs & derivatives/pharmacology
OTO - NOTNLM
OT  - Advanced glycation end products
OT  - Diabetic nephropathy
OT  - Inflammation
OT  - MAPK
OT  - NF-kappaB
OT  - TAK1
EDAT- 2015/12/22 06:00
MHDA- 2016/09/30 06:00
CRDT- 2015/12/22 06:00
PHST- 2015/08/12 00:00 [received]
PHST- 2015/10/21 00:00 [revised]
PHST- 2015/11/22 00:00 [accepted]
PHST- 2015/12/22 06:00 [entrez]
PHST- 2015/12/22 06:00 [pubmed]
PHST- 2016/09/30 06:00 [medline]
AID - S1043-4666(15)30112-5 [pii]
AID - 10.1016/j.cyto.2015.11.023 [doi]
PST - ppublish
SO  - Cytokine. 2016 Feb;78:62-8. doi: 10.1016/j.cyto.2015.11.023. Epub 2015 Dec 10.